Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
OptimizeRx Co. (NASDAQ:OPRX) – Analysts at William Blair dropped their Q4 2020 earnings per share estimates for shares of OptimizeRx in a research note issued to investors on Tuesday, November 5th. William Blair analyst R. Daniels now anticipates that the company will post earnings of $0.13 per share for the quarter, down from their previous estimate of $0.14.
OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.15). OptimizeRx had a negative return on equity of 4.19% and a negative net margin of 5.32%. The company had revenue of $5.00 million for the quarter, compared to the consensus estimate of $7.21 million.
OPRX has been the topic of a number of other research reports. B. Riley reduced their target price on OptimizeRx from $26.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday. Zacks Investment Research cut OptimizeRx from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, ValuEngine upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Wednesday.
OPRX traded down $0.35 during midday trading on Friday, reaching $10.13. 161,500 shares of the company were exchanged, compared to its average volume of 91,799. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.80 and a current ratio of 6.80. OptimizeRx has a one year low of $8.92 and a one year high of $17.24. The stock has a market capitalization of $170.46 million, a P/E ratio of 202.60, a PEG ratio of 1.50 and a beta of 0.42. The stock’s 50-day simple moving average is $13.49 and its 200 day simple moving average is $14.42.
Several large investors have recently added to or reduced their stakes in the company. Park West Asset Management LLC lifted its holdings in shares of OptimizeRx by 14.0% during the 2nd quarter. Park West Asset Management LLC now owns 1,088,088 shares of the company’s stock valued at $17,627,000 after purchasing an additional 133,238 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of OptimizeRx by 2,111.6% during the 2nd quarter. BlackRock Inc. now owns 607,292 shares of the company’s stock valued at $9,839,000 after purchasing an additional 579,833 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of OptimizeRx by 22.2% during the 2nd quarter. Vanguard Group Inc. now owns 511,060 shares of the company’s stock valued at $8,279,000 after purchasing an additional 93,015 shares in the last quarter. Wasatch Advisors Inc. lifted its holdings in shares of OptimizeRx by 24.2% during the 2nd quarter. Wasatch Advisors Inc. now owns 404,873 shares of the company’s stock valued at $6,559,000 after purchasing an additional 78,816 shares in the last quarter. Finally, Calamos Advisors LLC lifted its holdings in shares of OptimizeRx by 17.0% during the 3rd quarter. Calamos Advisors LLC now owns 312,764 shares of the company’s stock valued at $4,529,000 after purchasing an additional 45,548 shares in the last quarter. Institutional investors and hedge funds own 57.32% of the company’s stock.
In other OptimizeRx news, CEO William J. Febbo acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were acquired at an average price of $10.38 per share, for a total transaction of $51,900.00. Insiders own 8.40% of the company’s stock.
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Featured Story: Why is the Consumer Price Index (CPI) important?